FDA 510(k) for Israeli Startups: Complete Guide to Clearance

What is the FDA 510(k) pathway?

The FDA 510(k) is a premarket submission made to the FDA to demonstrate that a medical device is as safe and effective (substantially equivalent) to a legally marketed device (the "predicate device"). The name comes from section 510(k) of the Food, Drug, and Cosmetic Act. It is the pathway used for roughly 80% of all medical devices cleared for the US market.

510(k) applies to Class II devices — medium-risk devices. Examples: most imaging software (MRI, CT, ultrasound analysis software), many AI diagnostic tools, surgical instruments, dialysis equipment, infusion pumps. Class I devices (very low risk, like band-aids) are exempt from 510(k); Class III devices (high risk, like implantable defibrillators) require PMA, a much more demanding pathway.

The predicate device: the foundation of the submission

The entire 510(k) process centers on one document: your predicate device selection. The predicate is an existing FDA-cleared device that is similar to yours in intended use AND technological characteristics. Your job is to prove your device is "substantially equivalent" — same intended use, same or improved safety/effectiveness, no new questions of safety.

Choosing the right predicate is 50% of the work. If the predicate is too similar to an older technology, the FDA may question why your device isn't obviously better. If it's too different, the FDA may reject "substantial equivalence" and push you to the De Novo pathway (slower, more expensive). Most Israeli MedTech startups hire FDA regulatory consultants specifically for predicate selection — it's worth the $15-30K.

The 510(k) submission package

A typical 510(k) submission includes 20+ sections, totaling 200-800 pages: (1) Indications for Use Statement. (2) 510(k) Summary. (3) Device Description. (4) Substantial Equivalence Discussion. (5) Performance Testing — Bench (mechanical, electrical, software). (6) Performance Testing — Animal (if applicable). (7) Performance Testing — Clinical (required for some Class II devices, especially AI/ML-based). (8) Biocompatibility Testing. (9) Sterilization and Shelf Life. (10) Software Documentation (IEC 62304). (11) Electromagnetic Compatibility. (12) Labeling.

For AI/ML-based MedTech, additional requirements apply: Software as a Medical Device (SaMD) documentation, Good Machine Learning Practice, and training/validation dataset documentation. The FDA has been evolving its AI/ML guidance rapidly — a 2026 submission looks different from a 2022 submission.

Timeline: 3-12 months from submission to clearance

The official FDA review clock for 510(k) is 90 days, but it's often extended. Typical breakdown: (1) Acceptance review (5-15 days) — FDA confirms the submission is complete. (2) Substantive review (60-90 days) — FDA reviews the content. (3) Interactive review — FDA may send "Additional Information" requests. Each AI request stops the clock until the startup responds. (4) Final decision — clearance, not clearance, or request for more data.

Real-world clearance timelines: **3-4 months** for straightforward submissions with strong predicates and clean data. **6-9 months** for more complex devices or those requiring AI submissions. **9-12+ months** for novel technologies where the FDA requires multiple rounds of AI requests. WeCcelerate-Leumit typically achieves clearance in 4-6 months due to pre-submission FDA meetings and experienced regulatory consultants.

Cost: $150K-$500K all-in

The direct FDA fee for a 510(k) submission is $24,335 (FY2025, small business rate). The real cost is everything else: (1) Regulatory consultant — $50-150K (strongly recommended for first-time filers). (2) Performance testing — $20-100K (depends on device complexity). (3) Clinical data — $0-200K (not always required, but common for AI/ML). (4) Quality system documentation (ISO 13485) — $30-80K. (5) Medical writing — $20-50K. (6) Legal and company fees — $10-30K.

Total: $150K-$500K for most Class II devices. Plus 18-24 months of runway during the review. An Israeli startup aiming for US market needs to budget 30-50% of their Seed round for regulatory work alone.

Pre-submission meetings: the Israeli startup's secret weapon

The FDA offers free "Pre-Submission" (Q-Sub) meetings where you can present your proposed 510(k) strategy and get FDA feedback BEFORE spending hundreds of thousands on testing. Most Israeli startups skip this, thinking they'll just submit and hope. This is a mistake.

A Q-Sub meeting takes 2-3 months to schedule but provides written FDA feedback on your predicate selection, testing strategy, and clinical data requirements. Two Q-Sub meetings for an Israeli startup (at Seed and pre-submission) typically save 6-12 months of revision cycles. WeCcelerate-Leumit advises founders to budget for 2-3 Q-Sub meetings as standard practice.

How WeCcelerate-Leumit supports FDA 510(k) submissions

WeCcelerate-Leumit offers end-to-end FDA regulatory support: (1) Former FDA senior advisors on our advisory board. (2) Predicate device selection and substantial equivalence analysis. (3) Pre-Submission meeting preparation and coordination. (4) Performance testing protocols and CRO coordination. (5) Clinical data from Leumit pilots to support the submission. (6) Submission drafting and revision response. Typical clearance timeline: 4-6 months vs. 9-12 months for startups going alone.